Table 1.
Clinical Characteristics of 787 Cisplatin-treated Germ Cell Tumor Survivors According to Chemotherapy Regimen
| Characteristic | All Patients N = 787 | Chemotherapy Regimen | ||
|---|---|---|---|---|
| EPa n = 284 (%) |
BEP × 3b n = 342 (%) |
BEP × 4c n = 161 (%) |
||
| Median age at diagnosis, y (range) | 30.8 (15.2–52.5) | 32.3 (17.2–52.5) | 29.9 (15.2–49.7) | 28.8 (16.0–48.1) |
| Median age at clinical evaluation, y (range) | 37.3 (18.7–68.4) | 38.4 (20.0–68.4) | 36.9 (18.7–65.6) | 36.3 (20.0–59.1) |
| Histology | ||||
| Seminoma | 209 (26.6) | 99 (34.9) | 80 (23.4) | 30 (18.6) |
| Nonseminoma | 574 (72.9) | 184 (64.8) | 261 (76.3) | 129 (80.1) |
| Germ cell tumor NOSd | 4 (0.5) | 1 (0.4) | 1 (0.3) | 2 (1.2) |
| Primary site | ||||
| Testis | 724 (92.0) | 267 (94.0) | 319 (93.3) | 138 (85.7) |
| Extragonadal | 63 (8.0) | 17 (6.0) | 23 (6.7) | 23 (14.3) |
| Race | ||||
| White | 684 (86.9) | 241 (84.9) | 311 (90.9) | 132 (82.0) |
| Non-whitee | 103 (13.1) | 43 (15.1) | 31 (9.1) | 29 (18.0) |
| Marital status | ||||
| Not marriedf | 295 (37.5) | 107 (37.7) | 121 (35.4) | 67 (41.6) |
| Married/living as married | 492 (62.5) | 177 (62.3) | 221 (64.6) | 94 (58.4) |
| Education | ||||
| Less than college graduateg | 254 (32.3) | 73 (25.7) | 112 (32.7) | 69 (42.9) |
| College graduate or postgraduateh | 523 (66.5) | 210 (73.9) | 225 (65.8) | 88 (54.7) |
| Other or unknown | 10 (1.3) | 1 (0.4) | 5 (1.5) | 4 (2.5) |
| Mean cumulative cisplatin dose, mg/m2 (SD) | ||||
| <300 | 35 (4.5) | 1 (0.4) | 32 (9.4) | 2 (1.2) |
| 300 | 301 (38.3) | 2 (0.7) | 299 (87.4) | 0 |
| 301–399 | 24 (3.1) | 0 | 10 (2.9) | 14 (8.7) |
| 400 | 400 (50.8) | 273 (96.1) | 1 (0.3) | 126 (78.3) |
| >400 | 27 (3.4) | 8 (2.8) | 0 | 19 (11.8) |
| Cumulative bleomycin dose, IU | ||||
| 0 | 284 (36.1) | 284 (100) | 0 | 0 |
| >0–180,000 | 43 (5.5) | 0 | 24 (7.0) | 19 (11.8) |
| 181,000–270,000 | 342 (43.5) | 0 | 316 (92.4) | 26 (16.2) |
| 271,000–360,000 | 114 (14.5) | 0 | 2 (0.6) | 112 (69.6) |
| >360,000 | 4 (0.5) | 0 | 0 | 4 (2.5) |
| Time since completion of chemotherapy | ||||
| Median, y (range) | 4.2 (1.0–29.9) | 4.1 (1.0–23.9) | 4.0 (1.0–25.2) | 5.1 (1.0–29.9) |
| <2 | 196 (24.9) | 72 (25.4) | 95 (27.8) | 29 (18.0) |
| 2–5 | 292 (37.1) | 104 (36.6) | 125 (36.6) | 63 (39.1) |
| 6–9 | 138 (17.5) | 49 (17.3) | 58 (17.0) | 31 (19.3) |
| ≥ 10 | 161 (20.5) | 59 (20.8) | 64 (18.7) | 38 (23.6) |
Abbreviations: BEP = bleomycin, etoposide, and cisplatin; EP = etoposide and cisplatin; IU = International Units; NOS = not otherwise specified.
Of 284 patients who received EP, 2 received ≤ 3 cycles, 275 had 4 cycles, and 7 had ≥ 5 cycles.
Of 342 patients, 14 had ≤ 2 cycles of BEP, and 328 had 3 cycles of BEP.
Of 161 patients, 154 had 4 cycles of BEP, and 7 had ≥ 5 cycles of BEP.
Germ cell tumor, NOS includes 1 participant with unknown histology.
Non-white participants consisted of 7 Black/African American; 34 Asian; 1 American Indian; 1 Native Hawaiian Pacific Islander; 10 who designated more than one race; 30 other race; 15 who declined to answer (or unknown); and 5 for whom race was not stated.
Among 295 patients, 241 were single or never married, 45 were widowed or divorced or separated, and 9 patients did not report marital status.
Includes 79 patients with high school or less and 175 patients with training after high school or some college.
Includes 351 patients who were college graduates and 172 patients with postgraduate level.